Lisata Therapeutics, a company focused on therapies for advanced solid tumors and other serious diseases, has deepened its partnership with GATC Health Corp., an AI-driven drug discovery firm. This strategic alliance aims to dramatically improve the speed and success rate of drug development. Lisata will leverage GATC's proprietary Multiomics Advanced Technology® (MAT) platform, which uses AI to analyze complex biological interactions, predict drug efficacy and safety, and identify new combination therapies, including with Lisata's own drug candidate, certepetide. The collaboration's immediate focus is to advance a non-opioid small molecule for opioid use disorder (OUD), discovered by GATC's MAT platform, into Phase 1 human trials early next year. This initiative underscores the potential for AI to de-risk and accelerate the traditionally lengthy and expensive drug development process, with the companies anticipating a more efficient pathway to bring critical treatments to patients.